Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to reduce side effects of prostate cancer treatment

NCT ID NCT05526248

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times

Summary

This study looked at two drugs, darolutamide and enzalutamide, in men with prostate cancer that had returned after initial treatment but had not yet spread. The goal was to see how each drug affects testosterone levels and related side effects like breast tenderness. 28 men participated, taking one of the two drugs for up to a year, with regular blood tests and scans to monitor their cancer and overall health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center - Oncology

    Boston, Massachusetts, 02215, United States

  • Central Ohio Urology Group - Gahanna

    Gahanna, Ohio, 43230, United States

  • Mass General Cancer Center

    Boston, Massachusetts, 02114-2696, United States

  • Memorial Sloan Kettering Cancer Center New York - Main Campus

    New York, New York, 10065, United States

  • Unio Specialty Care - Urology - Sherman Oaks

    Sherman Oaks, California, 91411, United States

Conditions

Explore the condition pages connected to this study.